Heat Biologics has developed “Immune Pan-Antigen Cytotoxic Therapy” (ImPACT) for treatment of advanced cancers. ImPACT is an allogenic, gp96-Ig based immunotherapy that has proven safe and effective in a Phase I clinical trial for non-small cell lung cancer and is currently in Phase II trials. The strength of ImPACT's gp96-Ig approach is that it exposes the immune system to all of the antigens produced by a tumor cell bound to an immune-activating adjuvant. This provides a real advantage over other cancer vaccines that present only a single antigen or which lack an appropriate adjuvant. Given the promising results of ImPACT in lung cancer, Heat Biologics is initiating clinical trials for ImPACT against triple negative breast cancer (TNBC). We propose performing genechip genomic analyses of TNBC patients treated with Heat Biologics' ImPACT technology. TNBC is the most difficult subtype of breast cancer to treat, as it does not respond to receptor-directed therapy. Personalized medicine and biomarker development can help deliver the right treatments to the right patients for specific disease subtypes such as TNBC. In addition, our genomic analyses will help clarify the basic mechanisms of action for immunotherapeutic vaccine therapy on heterogenous patient tumor tissue samples. Our team has significant experience in biomarker development in breast cancer patients receiving neoadjuvant cisplatin treatment. Our unique approach can determine outcomes in small cohorts of patients, and is optimal for supporting immune endpoint
analysis in early phase clinical trials. Conducting genomic analysis for the ImPACT TNBC trials will provide significant data for both patient indications and mechanisms of next generation cancer immunotherapies.

Submitted on Nov 20, 2011

#GEidea6545

From Twitter User: @russell_hanson

Please support my proposal w/ HeatBio Triple Negative Breast Cancer gp96-Ig Based Immuno Cancer Vaccination #GEidea6545 http://t.co/nG1QOWqy

2 days ago by Healthymagination

Similar Ideas

- Personalized Immunotherapy for Triple Negative Breast Cancers
- TARGETING TRIPLE NEGATIVE BREAST CANCER WITH A NEW COMBINATORIAL SMALL INTERFERING RNA STRATEGY
- Injectable Probes for Improved Detection and Surgical Resection of Triple Negative Breast Cancer
- Predictive Markers for the...
Development of Personalized Therapies for Triple Negative Breast Cancer

Targeting Triple Negative Breast Cancers with Antibodies

© 2011 General Electric Company | GE.com | Contact Us | Terms | FAQ | Privacy

Terms and Conditions | Contact us: GEChallenge@brightidea.com

1.18302 seconds